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On December 8, 2016, the NEJM published a sounding board on Real World Evidence (RWE) 1 
by the US FDA leadership. While the value of RWE based on non-randomized observational 
studies was appreciated, such as for hypothesis generating, safety and measuring quality in 
healthcare delivery, the authors expressed concerns on the quality of data sources and the ability 
of methodologies to control for confounding.  In response, we offer a few considerations 
regarding these concerns.  
What are the challenges and the limitations of non-randomized observational studies? Can 
the advancement in the current methodology overcome these obstacles?  
Currently, our evidence-based decision making largely focuses on randomized controlled trial 
(RCT) based ‘efficacy’ studies rather than ‘effectiveness’ studies. Non-randomized observational 
studies make up the bulk of evidence in ‘real world’. Although, different types of RWE studies 
exist, the issues that we tend to address in this commentary are about observational studies, 
primarily the use of healthcare longitudinal databases with health insurance claims or electronic 
medical records (EMRs).2 These two types of databases are the most commonly used data 
sources to generate real world evidence when evaluating the use of medications and their 
effectiveness and safety in clinical practice or studying unmet need/disease burden. 
Confounding, selection bias and information bias constitute a major threat to the validity of non-
randomized observational studies. However, with appropriate newer study designs and advanced 
statistical analysis, such as appropriate use of propensity score methods, confounding or biases 
can often be eliminated or largely reduced. Incomplete data on key outcome measures, pre-
existing medical conditions/complications, or laboratory values from existing data sources can 
lead to skepticism on the quality and value of evidence based on those databases. Yet, validation 
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efforts, quality assurance programs, and sensitivity analysis can help improve or ensure the 
robustness of findings.   
The past decade witnessed some breakthroughs in methodological advancement for non- 
randomized observational studies. In some cases, well-done analysis with complex methodology 
of real world evidence could sometimes substitute or replicate the findings from RCT2. Uptake 
of the new user and active comparator study designs3 have also gone a long way in mitigating 
confounding, as well as other forms of bias common in observational studies.  The use of 
multiple imputation with chained equations in combination with other analytic techniques have 
improved the way we deal with incomplete or missing data on important confounding 
variables.4,5 With the application of propensity score methodology and analytic techniques 
specifically targeting big data, including machine learning, we are becoming much closer to the 
quality of evidence expected in the context of RCTs. Propensity score methodology can address 
measured confounding factors well, even in the setting of rare outcomes, whereas conventional 
RCTs may be low of power.6 In the context of large datasets, predictive models with machine 
learning techniques can guide in the appropriate selection of variables for the estimation of 
propensity scores. In certain settings, high-dimensional propensity score methodology can 
generate valid effect estimates when benchmarked against results expected from randomized 
trials.7 Sensitivity analyses can help researchers understand the robustness of results, just as such 
analyses play a role in RCTs. The choice of the study design and the selection of the data source 
should be directed by the scientific question of interest, and should consider whether a RCT is 
feasible and/or appropriate. In the context of a non-interventional observational study, 
researchers should consider a feasibility assessment to determine if a selected data source 
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contains sufficient and reliable information on outcomes and important confounding variables to 
answer the specific research question of interest.   
As our data collection systems evolve, the completeness and data quality of large longitudinal 
health insurance claims and EMRs databases are being enhanced on an ongoing basis. With 
rapidly evolving technology supporting linkage across multiple sources of information, e.g., 
claims, registries, EMRs and biobanks, ability to control for residual confounding are rapidly 
improving. Moreover, other available methods such as instrumental variable analysis may help in 
the context of unmeasured confounding if used appropriately.8 
Can non-randomized observational studies generate high-level quality evidence for 
decision making? Does evidence quality rely on randomized control trials alone? 
Well-designed and controlled RCTs are recognized as the ‘gold standard’ to assess medication 
efficacy, whereas non-randomized observational studies are often proposed as a substitute when 
RCTs are not available or not feasible. Blinding is an important methodologic feature of RCTs to 
minimize bias and maximize validity of results, and can have an important impact on outcome 
ascertainment and post-randomization decisions. Typically, observational studies are not blinded 
but certain aspects (outcome assessment or adjudication) can be blinded to reduce bias. 
However, the bias from lack of blinding is less pronounced for objective outcomes. The concerns 
regarding the quality of evidence from non-randomized observational studies are largely 
attributable to the ‘non-randomized’ design; yet methodological advances can often address 
confounding. More attention <rather than on randomization and blinding> is warranted on 
limiting potential selection bias and on assessing whether the population and outcomes can be 
reliably defined for the specific scientific question in the selected data source.  
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Many systematic reviews have compared the evidence obtained from RCTs versus non-
randomized studies, and shown little evidence for meaningful differences in effect estimates 
between non-randomized studies and RCTs when the same research question was being 
addressed in the same population, regardless of specific observational study design, 
heterogeneity, or inclusion of studies of pharmacological interventions.9 Evaluation of several 
key questions could serve to inform when and how the findings from non-randomized 
observational studies could substitute for that of RCTs.2  
Evidence from non-randomized observational studies and RCTs are complementary and additive 
to the overall body of evidence. Both types of studies should be critically appraised and used for 
decision making. The availability of RCTs should not make non-randomized observational 
studies unnecessary, and vice versa. If both types of studies are available and answer the same 
question, they should all contribute to the body of evidence. Existing guidelines on the 
evaluation of the quality of evidence based on non-randomized observational studies can assist in 
this regard. While RCTs will continue to generate high-quality evidence that will determine and 
guide our treatments, large non-randomized observational studies are also powerful resources, 
especially in the area of comparative effectiveness research and can help answer appropriate 
scientific questions.10 
The following key guidelines can be used to evaluate the quality of published non-randomized 
observational studies where health insurance claims and EMR databases are used:  
• A checklist For Retrospective Database Studies – Report of The ISPOR Task Force On 




• Good ReseArch for Comparative Effectiveness (GRACE) Checklist and Principles (can 
be found here: https://www.graceprinciples.org/grace.html)  
• International Society for Pharmacoepidemiology (ISPE) Guidelines for Good 
Pharmacoepidemiology Practices (GPP) (can be found here: 
https://www.pharmacoepi.org/resources/policies/guidelines-08027/)  
• STrengthening the Reporting of OBservational studies in Epidemiology (STROBE) (can 
be found here: https://www.strobe-statement.org/index.php?id=strobe-home)  
• The REporting of studies Conducted using Observational Routinely-collected health Data 
(RECORD) Statement (can be found here: 
http://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1001885)  
• International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Good 
Practices for Outcomes Research Reports (can be found here: 
https://www.ispor.org/research_initiatives/hs_initiatives.asp)  
• Methodological Standards for Patient-Centered Outcomes Research (PCOR) by the 
Patient Centered Outcomes Research Institute (PCORI) (can be found here: 
https://www.pcori.org/research-results/about-our-research/research-methodology/pcori-
methodology-standards)  
• Guide on Methodological Standards in Pharmacoepidemiology by the European Network 
of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) (can be found 
here: http://www.encepp.eu/standards_and_guidances/methodologicalGuide.shtml)  
Most recently, the ISPOR and the ISPE created the joint Task Force to make recommendations 
on non-randomized observational studies regarding 1) transparency in the reporting of study 
methodology, 2) reproducibility and replicability of findings.  These documents highlight the 
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importance of replicability across different data sources and different methods, and the 
importance of providing sufficient detail to allow such replication. Transparency and 
replicability would substantially increase our confidence on the validity of observational studies 
and can offer a trustworthy base for the expanded use of RWE in healthcare decision making. 
What is our recommendation regarding the use of RWE for decision making? 
The current paradigm of evidence hierarchy in evidence-based decision making needs to be 
reviewed. We believe the validity of evidence may not necessarily solely depend on whether it is 
generated by ‘randomized’ or ‘non-randomized’ studies. Well-designed, well-executed and well-
reported non-randomized observational studies are a critical component of the overall body of 
evidence. A framework from the FDA with scientific considerations for study design, population 
identification, outcome ascertainment, reducing potential biases, and analysis could be helpful in 
encouraging researchers to apply best practices. The use of RWE based on such studies should 
be considered more broadly in various decision making settings, including clinical practice, 
Health Technology Assessment (HTA), regulatory and post-marketing lifecycle management. In 
an era of pay-for-value and adaptive pathway in formulary and reimbursement decision making, 
we recommend a paradigm shift from largely relying on idealized RCT evidence, which may fail 
to reflect the true value of the drug or medical device to more realistic RWE supported by high-
quality data and robust methodology where the strengths and limitations of the generated data 
can be acknowledged. Another important future step would be for academic institutions to 
develop, and funding agencies to support development of high quality healthcare databases, and 
rigorous educational training and fellowship programs to foster next-generation researchers and 
leaders.  Educational efforts should also be extended to other healthcare stakeholders, including 
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clinicians, policy decisions makers and industry, to guide the appropriate understanding and use 
of RWE.  
We are encouraged by the FDA’s effort to enhance the use of RWE in regulatory decision 
making, e.g. the recent draft guidance on RWE for medical devices. As RWE can be critical in 
the evaluation of both safety and effectiveness of medications, we appreciate that FDA is taking 
further steps moving in this direction by developing a framework and draft guidance (no later 
than the end of 2021) on how RWE can contribute to the assessment of safety and effectiveness 
in regulatory assessment, such as in the approval of new indications.  
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